

# SEAGEN INC.

ISIN: US81181C1045

WKN: 81181C104

Asset Class: **Stock**

## Company

2022/05/16 20:49:53



Price

**141.31**

USD

Difference

4.19%(5.68)



## Contact Details

SEAGEN INC.

Tel: 1-425-527-4000

--

Fax: -

21823 30th Drive SE

Web: <http://www.seattlegenetics.com>

98021 Bothell

E-mail: [contact@seagen.com](mailto:contact@seagen.com)

## Company Profile

Seagen Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997, and is headquartered in Bothell, WA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2021		2020		2019	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	2,869,194,000		3,062,384,000		1,176,641,000	
<b>Common stock capital</b>		183,000		181,000		172,000
<b>Fixed assets</b>	850,410,000		938,522,000		1,029,225,000	
<b>Equity capital of a company</b>		3,065,139,000		3,488,100,000		1,876,287,000
<b>Cash and cash equivalents</b>	424,834,000		558,424,000		274,562,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		568,854,000		388,138,000		259,357,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		85,611,000		124,668,000		70,222,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		28,946,000		62,784,000		2,615,000
<b>Total assets</b>	3,719,604,000	3,719,604,000	4,000,906,000	4,000,906,000	2,205,866,000	2,205,866,000

## Balance notes

	2021	2020	2019
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	2,675	2,092	1,605
<b>Equity ratio</b>	82.40%	87.18%	85.06%
<b>Debt-equity ratio</b>	21.35%	14.70%	17.57%

## Others

	2021	2020	2019
<b>Tax Expense Rate</b>	0.18%	0.33%	0.00%

# SEAGEN INC.

ISIN: US81181C1045

WKN: 81181C104

Asset Class: **Stock**

## Income statement

	2021	2020	2019
<b>Turnover</b>	1,574,371,000	2,175,536,000	916,713,000
<b>Net income</b>	-674,471,000	613,670,000	-158,650,000
<b>EBIT</b>	-652,657,843	586,308,202	-164,217,676
<b>Operating income before taxes</b>	-675,705,000	615,701,000	-158,650,000
<b>Cash Flow</b>	-484,619,000	867,839,000	-157,077,000
<b>Net interest income</b>	1,607,000	7,245,000	11,771,000
<b>Research and development expenses</b>	1,228,672,000	827,129,000	719,374,000
<b>Income taxes</b>	-1,234,000	2,031,000	0
<b>Result from investments in subsidiaries, associates and other</b>	0	0	0
<b>Revenues per employee</b>	567,127	1,002,078	550,370

## Board of Directors

## Members of Management Board

Alpna Seth	Member of Board of Directors
Felix Baker	Member of Board of Directors
Marc Lippman	Member of Board of Directors
Nancy Simonian	Member of Board of Directors
Ted Love	Member of Board of Directors
Daniel Welch	Member of Board of Directors
David Gryska	Member of Board of Directors
John Orwin	Member of Board of Directors
Roger Dansey	Chairman of Managing Board
Dennis Benjamin	Member of Executive Committee
Vaughn Himes	Member of Executive Committee
Christopher Pawlowicz	Member of Executive Committee
Jean Liu	Member of Executive Committee
Natasha Hernday	Member of Executive Committee
Peggy Pinkston	Member of Executive Committee
Todd Simpson	Member of Executive Committee